Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24th In January, Acceleron reported that the PULSAR Phase 2 trial in patients ...
(Reuters) -Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring ...
Just months after striking its $11.5 billion deal for Acceleron Pharma, Merck & Co. has telegraphed its plans to cut back at its newly acquired unit. Merck is laying off a clutch of Acceleron staffers ...
Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-oncology megablockbuster Keytruda, but ...
Which large pharma company is preparing to splash $11 billion to acquire Acceleron? That is the question raised by an article in Bloomberg, which reports an unidentified large pharma company is in ...
Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular ...
- Data presented show maintained or improved responses in multiple efficacy endpoints among patients treated with sotatercept plus stable background therapy for up to 48 weeks - - Patients receiving ...
Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs and heart. Merck will pay $180 per share in cash for ...
Merck said Sept. 30 it will acquire Acceleron Pharma for about $11.5 billion to expand its rare disease drug portfolio. Merck will pay Acceleron $180 per share in cash. Acceleron develops drugs to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...
Sept 30 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday it would buy Acceleron Pharma Inc (XLRN.O), opens new tab for about $11.5 billion, broadening its portfolio beyond aging cancer ...
Merck & Co. said Thursday it would buy Acceleron Pharma Inc. for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results